Eli Lil­ly promis­es five new ap­provals in next two years with Alzheimer’s at the fore­front

Eli Lil­ly set an am­bi­tious goal be­fore its in­vestor day on Wednes­day, promis­ing to have new five ap­proved drugs in the next two years.

Those five will be led by do­nanemab, the an­ti-amy­loid an­ti­body for Alzheimer’s dis­ease for which Lil­ly ex­pects to com­plete a rolling sub­mis­sion in 2022’s first quar­ter. Lil­ly is at­tempt­ing to use the same ac­cel­er­at­ed ap­proval path­way con­tro­ver­sial­ly grant­ed to Bio­gen for ad­u­canum­ab ear­li­er this year and plans to pit the drugs head-to-head in a Phase III study.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER